Previous close | 8.55 |
Open | 8.63 |
Bid | 7.35 x 800 |
Ask | 8.93 x 1000 |
Day's range | 8.43 - 8.63 |
52-week range | 6.15 - 11.52 |
Volume | |
Avg. volume | 10,380 |
Market cap | 70.553M |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.54 |
Earnings date | 09 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 24.83 |
AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session following the prepared remarks. Investo
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences: Event:H.C. Wainwright 2022 Global Investment Conference – May 23rd – 26thPresentation:Live presentation May 25th at 4:00 – 4:30 PM EDTWebcast link:Here Event:Jefferies Healthcare Conference – June 8th – 10thPresentation: Live fireside chat